Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine

Vladimir M. Pisarev, Prahlad Parajuli, R. Lee Mosley, Jennifer Sublet, Linda Kelsey, Prem S. Sarin, Daniel H. Zimmerman, M. Douglas Winship, James E. Talmadge

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Liposomes and Flt3 ligand (Flt3L), a ligand for the fms-like tyrosine kinase receptor Flt3/ FLK2, can augment the immune response to an HIV peptide vaccine. The HGP-30 peptide used in these studies is a synthetic peptide that corresponds to a highly conserved region of HIV-1 p17 gag (amino acids 86-115). Mice were immunized with HGP-30 or HGP-30 conjugated to keyhole limpet hemocyanin (KLH) and delayed-type hypersensitivity (DTH) responses, antibody (IgG) amount and antigen-specific proliferative responses by spleen cells were used to monitor the immune response. Daily injections of Flt3L prior to HGP-30 administration enhanced significantly an antigen-specific lymphocyte proliferation response when compared with Flt3L, HGP-30 alone or HGP-30 containing liposomes. Intravenous administration of HGP-30 was superior to intramuscular (i.m.) immunization for the induction of DTH responses. The HGP-30/KLH containing liposomes enhanced both DTH and antibody responses, while liposomes containing HGP-30 peptide elicited only T cell responses. In these studies, either Flt3L or liposomes increased DTH responses compared with the i.m. injection of the HGP-30 vaccine alone. Copyright (C) 2000 International Society for Immunopharmacology. Published by Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)865-876
Number of pages12
JournalInternational Journal of Immunopharmacology
Issue number11
StatePublished - 2000


  • Flt3 ligand
  • HGP-30 peptide
  • HIV-1 p17 gag

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Fingerprint Dive into the research topics of 'Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine'. Together they form a unique fingerprint.

Cite this